Enterprise Value
115.8M
Cash
54.42M
Avg Qtr Burn
-51.8M
Short % of Float
7.45%
Insider Ownership
7.73%
Institutional Own.
50.81%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Giroctocogene fitelparvovec (SB-525 / PF-07055480) Details Blood disorder, Rare diseases, Hemophilia, Rare genetic disease | Phase 3 Update | |
TX-200 Details Kidney disease, Kidney transplantation | Phase 1/2 Data readout | |
ST-920 (isaralgagene civaparvovec) Details Fabry disease, Rare genetic disease | Phase 1/2 Update | |
BIVV003 (SAR445136) Details Sickle cell disease, Blood disorder | Failed Discontinued | |
ST-400 Details Blood disorder, Beta thalessemia | Failed Discontinued | |
SB-913 Details Genetic disorder, Rare diseases, Mucopolysaccharidoses, Rare genetic disease, Mucopolysaccharidosis type II | Failed Discontinued |